Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6709842
DNA encoding a growth factor specific for epithelial cells
expired -
US 6706754
Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
expired -
US 6706873
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
expired -
US 6703046
Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
expired -
US 6699835
Formulation of boronic acid compounds
expired -
US 6699842
Dominant negative deletion mutants of C-jun and their use in the prevention and treatment of cancer
expired -
US 6699674
Expression and refolding of truncated recombinant major outer membrane protein antigen (R56) of orientia tsutsugamushi and its use in antibody based detection assays and vaccines
expired -
US 6696064
Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy
expired -
US 6696242
Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
expired -
US 6696562
Avian astrovirus
expired -
US 6692964
Methods for transfecting T cells
expired -
US 6689367
Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
expired -
US 6689560
Raf protein kinase therapeutics
expired -
US 6689383
Chromium-histidine complexes as nutrient supplements
expired -
US 6685941
Methods of treating autoimmune disease via CTLA-4Ig
expired -
US 6685949
Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
expired -
US 6685944
Modified HCV peptide vaccines
expired -
US 6685948
Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
expired -
US 6686333
Inhibition of HIV replication using soluble Tat peptide analogs
expired -
US 6685933
Interferon &agr; hybrids
expired -
US 6682758
Water-insoluble drug delivery system
expired -
US 6682741
&bgr;2 microglobulin fusion proteins and high affinity variants
expired -
US 6682728
Efficient and selective adenoviral-mediated gene transfer into vascular neointima
expired -
US 6680176
Identification of candidate ligands which modulate antigen presenting cells
expired -
US 6680060
Hepatitus A virus vaccines
expired -
US 6680374
Invaplex from gram negative bacteria, method of purification and methods of use
expired -
US 6676936
Chimeric and/or growth-restricted flaviviruses
expired -
US 6676973
Method of treating ovarian cancers with cadmium
expired -
US 6673342
Recombinant human IgA-J chain dimer
expired -
US 6673905
Conjugation of biomolecules using Diels-Alder cycloaddition
expired -
US 6673559
Met proto-oncogene and a method for predicting breast cancer progression
expired -
US 6669962
Starch microcapsules for delivery of active agents
expired -
US 6669935
Delivery of therapeutic agents by gene therapy
expired -
US 6670374
Swainsonine compounds as inhibitors of toxin receptor expression
expired -
US 6664374
Polypeptides comprising IL-6 ligand-binding receptor domains
expired -
US 6664227
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
expired -
US 6664263
1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity
expired -
US 6660488
Antibodies for the alpha platelet-derived growth factor receptor
expired -
US 6660273
Chimeric vaccine against tick-borne encephalitis virus
expired -
US 6660750
Flavopiridol methods and compositions for HIV therapy
expired -
US 6656930
Aralkyl diazabicycloalkane derivatives for CNS disorders
expired -
US 6656706
Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
expired -
US 6653505
3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same
expired -
US 6653084
Anti-erbB-2 antibodies to human receptor related to but distinct from EGF receptor
expired -
US 6649621
Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
expired -
US 6649411
Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
expired -
US 6642049
Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38-bone marrow stem cells
expired -
US 6641815
Sequestrin
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory